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median OS from SBRT is 2.2 years (95%CI, 1.2 to 2.7 years), 
and the median OS from surgery is 5.0 years (95%CI, 3.9 to 
6.8 years). 
 
 
 
Conclusions: Our results demonstrate that SBRT after surgery 
brings about a good prognosis with low toxicity. SBRT may be 
a good treatment option for intrapulmonary recurrence after 
lung cancer surgery.  
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Purpose/Objective: Stereotactic Ablative Radiotherapy 
(SABR) has now become a primary option for medically 
inoperable patients with early stage non-small cell lung 
cancer (NSCLC). Many retrospective and prospective studies 
have showed that SABR can achieve local control rates of 
approximately 90%, offering a significant survival advantage 
over conventional radiotherapy with specific survival rates 
comparable to those of surgery. The aim of this retrospective 
study was to evaluated the clinical outcomes in patients 
affected with stage I NSCLC, medically inoperable, treated 
with SABR. 
Materials and Methods: Between 2003 and 2012, 110 
consecutive patients with stage I NSCLC were treated with 
SABR. The median age was 77 years (range 48-96 years). 
Histological/cytological diagnosis was obtained in 56 patients 
(50,9 %). The remaining 54 patients (49.1%) were included in 
the study if both FDG-PET was positive and tumor had 
increased in size at a second CT scan performed at least after 
a three months interval. Eighty-five patients (77.3%) had 
stage IA (T1N0M0 in 48 cases and T1bN0M0 in 37 cases, 
respectively) and 25 patients (22.7%) had stage IB (T2aN0M0), 
according to the 7th edition of the TNM classification and 
staging system for lung cancer. One hundred and three 
patients were medically inoperable because of the presence 
of medical comorbidities, poor pulmonary function or 
advanced age; 7 patients refused surgery. In 98 cases (89%) 
the localization of the tumor was peripheral; in 12 cases 
(11%) the localization was central. All patients were treated 
with 3D-CRT, consisting in 7-12 non-coplanar static fields 
conformed by mean of a multi leaf collimator (MLC). Dose 
and fractionation were chosen depending on size and location 
of the tumor. RTOG score were used for grading acute and 
late toxicity. 
Results:  Median follow-up time was 24.2 months (range 3-
123 months). One-year and 3-year local control was 95% and 
75%, respectively. Forty-one patients (45.1%) had at least one 
failure (local and/or nodal and/or distant), with a median 
time to any recurrence of 18.5 months. Disease free survival 
(DFS) rate at 3 years was 53%. Overall survival (OS) at 3 and 5 
years was 70% and 47%, respectively. Grade 1 acute 
pulmonary toxicity was observed in two patients (1.8%). Late 
pulmonary toxicity was recorded in 7 patients (6.3%) as: G1 in 
3, G2 in 3 and G3 in 1 patients, respectively. Seventy-four 
patients (67.3%) developed late radiological toxicity as: G1 in 
66, G2 in 7 and G3 in 1 patients, respectively. 
Conclusions: The results of this study support the routine use 
of SABR for stage I NSCLC, due to high local control and 
limited toxicity.  
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Purpose/Objective: Several investigators suggest that 
pretreatment blood parameters can be useful in determining 
the prognosis of non-small cell lung cancer (NSCLC). The 
relevance of readily available and commonly recorded blood 
parameters for long-term outcome of curative radio-
chemotherapy for NSCLC is, however, only partially 
determined.  
Materials and Methods: The analysis included 104 patients 
with stage IIIAN2 or III B non-small cell lung cancer (64 
squamous cell, 18 adenocarcinoma, 22 NOS). All patients had 
platin-based induction chemotherapy and radiotherapy with 
curative intent (60-74 Gy, 1,8-2.0 Gy/fraction). Twenty 
routinely recorded parameters from automated blood cell 
counter (blood cell number, mean cell volume, distribution 
width, hemoglobin concentration etc.) as well as erythrocyte 
sedimentation rate (ESR), osteopontin concentration (OP) and 
ratios of those parameters were considered in the analysis. 
Clinical parameters of known prognostic potential were also 
included (age, sex, general performance status, T, N stage, 
smoking history). Univariate and multivariate Cox 
proportional hazard regression model was used to select 
variables that had significant and independent impact on 
overall survival. The model performance was assessed with 
respect to 3-year overall survival by calculating the AUC 
(area under the curve) using ROC analysis. 
